Table 2 |
||
|
Treatment response. |
||
|
Treatment group |
ALN* (n = 245) |
MAS3** (n = 245) |
|
|
||
|
Compliance, no. (%) |
||
|
Completed day 7 |
241 (99.6%) |
240 (99.2%) |
|
Completed day 28 |
232 (95.9%) |
233 (96.3%) |
|
Completed day 42 |
225 (93.0%) |
227 (93.4%) |
|
Cumulative proportion of patients with clinical failure, no (%) |
||
|
Day 7 |
0 (0) |
0 (0) |
|
Day 28 |
13 (5.6) |
14 (6.0) |
|
Day 42 |
27 (12.0) |
24 (10.6) |
|
PCR, no. |
||
|
Novel |
23 |
14 |
|
Recrudescent |
2 |
8 |
|
Novel + recrudescent |
1 |
1 |
|
Indeterminate/missing |
1 |
1 |
|
PCR-adjusted cure rates, no. (%) |
||
|
Day 7 |
0 (100) |
0 (100) |
|
Day 28 |
2 (99.1) |
9(96.1) |
|
Day 42 |
3 (98.8) |
9 (96.3) |
|
|
||
|
* ALN = artemether-lumefantrine, ** MAS3 = artesunate-mefloquine |
||
|
Hutagalung et al. Malaria Journal 2005 4:46 doi:10.1186/1475-2875-4-46 |
||
